Hypoxia enhances the malignant nature of bladder cancer cells and concomitantly antagonizes protein O-glycosylation extension
Metrics: PDF 2572 views | HTML 4316 views | ?
Andreia Peixoto1,2,3,4,*, Elisabete Fernandes1,3,4,5,*, Cristiana Gaiteiro1,*, Luís Lima1,3,6, Rita Azevedo1,4, Janine Soares1, Sofia Cotton1, Beatriz Parreira1, Manuel Neves1,4, Teresina Amaro7, Ana Tavares1,7, Filipe Teixeira8, Carlos Palmeira1,9, Maria Rangel10, André M.N. Silva11, Celso A. Reis3,4,6,12, Lúcio Lara Santos1,9,13, Maria José Oliveira2,3, José Alexandre Ferreira1,3,4,6,14
1Experimental Pathology and Therapeutics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal
2New Therapies Group, INEB-Institute for Biomedical Engineering, Porto, Portugal
3Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal
4Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal
5Biomaterials for Multistage Drug and Cell Delivery, INEB-Institute for Biomedical Engineering, Porto, Portugal
6Glycobiology in Cancer, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal
7Department of Pathology, Hospital Pedro Hispano, Matosinhos, Portugal
8LAQV-REQUIMTE, Faculty of Sciences of the University of Porto, Porto, Portugal
9Health School of University Fernando Pessoa, Porto, Portugal
10UCIBIO-REQUIMTE, Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal
11UCIBIO-REQUIMTE/Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Porto, Portugal
12Department of Pathology and Oncology, Faculty of Medicine, Porto University, Porto, Portugal
13Department of Surgical Oncology, Portuguese Institute of Oncology, Porto, Portugal
14Porto Comprehensive Cancer Center (P.ccc), Porto, Portugal
*These authors contributed equally to this work
José Alexandre Ferreira, email: [email protected]
Keywords: glycosylation, bladder cancer, hypoxia, invasion, sialyl-Tn
Received: September 24, 2015 Accepted: July 26, 2016 Published: August 12, 2016
Invasive bladder tumours express the cell-surface Sialyl-Tn (STn) antigen, which stems from a premature stop in protein O-glycosylation. The STn antigen favours invasion, immune escape, and possibly chemotherapy resistance, making it attractive for target therapeutics. However, the events leading to such deregulation in protein glycosylation are mostly unknown. Since hypoxia is a salient feature of advanced stage tumours, we searched into how it influences bladder cancer cells glycophenotype, with emphasis on STn expression. Therefore, three bladder cancer cell lines with distinct genetic and molecular backgrounds (T24, 5637 and HT1376) were submitted to hypoxia. To disclose HIF-1α-mediated events, experiments were also conducted in the presence of Deferoxamine Mesilate (Dfx), an inhibitor of HIF-1α proteasomal degradation. In both conditions all cell lines overexpressed HIF-1α and its transcriptionally-regulated protein CA-IX. This was accompanied by increased lactate biosynthesis, denoting a shift toward anaerobic metabolism. Concomitantly, T24 and 5637 cells acquired a more motile phenotype, consistent with their more mesenchymal characteristics. Moreover, hypoxia promoted STn antigen overexpression in all cell lines and enhanced the migration and invasion of those presenting more mesenchymal characteristics, in an HIF-1α-dependent manner. These effects were reversed by reoxygenation, demonstrating that oxygen affects O-glycan extension. Glycoproteomics studies highlighted that STn was mainly present in integrins and cadherins, suggesting a possible role for this glycan in adhesion, cell motility and invasion. The association between HIF-1α and STn overexpressions and tumour invasion was further confirmed in bladder cancer patient samples. In conclusion, STn overexpression may, in part, result from a HIF-1α mediated cell-survival strategy to adapt to the hypoxic challenge, favouring cell invasion. In addition, targeting STn-expressing glycoproteins may offer potential to treat tumour hypoxic niches harbouring more malignant cells.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.